The prognostic and predictive value of AR-V7 quantification in mCRPC.

Adam Sharp,Jon Welti,Maryou Lambros,David Dolling,Caterina Aversa,Lorna Pope,Daniel Nava Rodrigues,Ines Figueiredo,Pasquale Rescigno,Michael Kolinsky,Ruth Riisnaes,Penelope Flohr,Diletta Bianchini,Robert Chandler,Joaquin Mateo,Nina Tunariu,Stephen R. Plymate,Jun Luo,Johann S. de Bono

The prognostic and predictive value of AR-V7 quantification in mCRPC.

2018

Adam Sharp
Jon Welti
Maryou Lambros
David Dolling
Caterina Aversa
Lorna Pope
Daniel Nava Rodrigues
Ines Figueiredo
Pasquale Rescigno
Michael Kolinsky
Ruth Riisnaes
Penelope Flohr
Diletta Bianchini
Robert Chandler
Joaquin Mateo
Nina Tunariu
Stephen R. Plymate
Jun Luo
Johann S. de Bono

12026Background: Androgen receptor splice variant-7 (AR-V7) is associated with resistance to abiraterone/enzalutamide treatment in metastatic castration resistant prostate cancer (mCRPC). Methods: ...

Keywords:

Pathology
Medicine
Enzalutamide
Abiraterone
Prostate cancer
Oncology
Internal medicine
predictive value
castration resistant
Androgen receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations